PHK
CPRX icon

Point72 Hong Kong’s Catalyst Pharmaceutical CPRX Stock Holding History

Point72 Hong Kong’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,054
Closed -$17.7K – 587
2023
Q4 		$17.7K Buy
+1,054
New +$14.4K ﹤0.01% 552
2022
Q3 		– Sell
-1,951
Closed -$14K – 1999
2022
Q2 		$14K Sell
1,951
-7,719
-80% -$56.6K ﹤0.01% 1625
2022
Q1 		$80K Buy
9,670
+3,738
+63% +$26.4K ﹤0.01% 1208
2021
Q4 		$40K Buy
5,932
+2,713
+84% +$17.8K ﹤0.01% 1389
2021
Q3 		$17K Buy
+3,219
New +$17.6K ﹤0.01% 1719
2020
Q4 		– Sell
-565
Closed -$2K – 1772
2020
Q3 		$2K Buy
+565
New +$2.21K ﹤0.01% 1116
2020
Q1 		– Sell
-3,517
Closed -$13K – 1023
2019
Q4 		$13K Buy
+3,517
New +$16.4K ﹤0.01% 958

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Hong Kong's CPRX Position: Q1 2024 in Review

Point72 Hong Kong sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 1,054 shares — an estimated $17.7K sold.

Point72 Hong Kong first reported a position in CPRX in Q4 2019 and held it in 7 quarters. The position peaked at $80K in Q1 2022. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Point72 Hong Kong reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Point72 Hong Kong sold 1,054 Catalyst Pharmaceutical shares in Q1 2024, an estimated $17.7K.
  • Point72 Hong Kong first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 7 quarters.
  • Point72 Hong Kong's Catalyst Pharmaceutical position peaked at $80K in Q1 2022.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Point72 Hong Kong's 13F filing for Q1 2024, filed 15 May 2024.